Krystal Biotech (KRYS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $316.58, -4.07% vs the prior close of $330.00.
- Volume 226.22K shares, 0.9x its 50-day average.
- New SEC filings: 8-K (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
KRYS slides 4.1% to $316.58, a 1-month low. Closed at $316.58, -4.07% vs the prior close of $330.00. Day range $315.39–$331.02, opened at $329.94.
KRYS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — KRYS slides 4.1% to $316.58, a 1-month low
- Closed at $316.58, -4.07% vs the prior close of $330.00. Day range $315.39–$331.02, opened at $329.94.
- Volume was 226.22K shares, 0.9x its 50-day average of 252.59K.
- Price is -6.8% vs its 50-day average ($339.77) and +3.6% vs its 200-day average ($305.47).
- 52-week range $183.03–$382.54; today's close sits at 67% of that range, 17.2% below the 52-week high.
Oct 15, 2026 — KRYS ends flat (-0.2%) to $330.00
- Closed at $330.00, -0.21% vs the prior close of $330.69. Day range $328.51–$338.91, opened at $332.98.
- Volume was 288.00K shares, 1.1x its 50-day average of 253.33K.
- Price is -2.9% vs its 50-day average ($339.90) and +8.2% vs its 200-day average ($305.13).
- 52-week range $183.03–$382.54; today's close sits at 74% of that range, 13.7% below the 52-week high.
- SEC filings that day: 8-K.
Oct 14, 2026 — KRYS rises 3.0% to $330.69
- Closed at $330.69, +2.97% vs the prior close of $321.16. Day range $319.01–$330.96, opened at $320.41.
- Volume was 277.40K shares, 1.1x its 50-day average of 258.47K.
- Price is -2.7% vs its 50-day average ($339.81) and +8.5% vs its 200-day average ($304.75).
- 52-week range $181.44–$382.54; today's close sits at 74% of that range, 13.6% below the 52-week high.
Oct 13, 2026 — KRYS slides 3.3% to $321.16, a 1-month low
- Closed at $321.16, -3.29% vs the prior close of $332.07. Day range $320.95–$331.93, opened at $331.48.
- Volume was 281.30K shares, 1.0x its 50-day average of 276.28K.
- Price is -5.5% vs its 50-day average ($339.69) and +5.5% vs its 200-day average ($304.35).
- 52-week range $179.19–$382.54; today's close sits at 70% of that range, 16.0% below the 52-week high.
Oct 12, 2026 — KRYS ends flat (+0.1%) to $332.07, 3 up days in a row
- Closed at $332.07, +0.14% vs the prior close of $331.61. Day range $328.53–$334.27, opened at $329.14.
- Volume was 168.10K shares, 0.6x its 50-day average of 282.69K — lighter than usual.
- Price is -2.2% vs its 50-day average ($339.52) and +9.2% vs its 200-day average ($304.00).
- 52-week range $179.19–$382.54; today's close sits at 75% of that range, 13.2% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — KRYS rises 1.3% to $331.61
- Closed at $331.61, +1.32% vs the prior close of $327.30. Day range $323.87–$333.56, opened at $326.55.
- Volume was 196.90K shares, 0.7x its 50-day average of 284.79K.
- Price is -2.4% vs its 50-day average ($339.70) and +9.2% vs its 200-day average ($303.61).
- 52-week range $179.19–$382.54; today's close sits at 75% of that range, 13.3% below the 52-week high.
Oct 8, 2026 — KRYS rises 0.8% to $327.30
- Closed at $327.30, +0.84% vs the prior close of $324.57. Day range $319.58–$332.11, opened at $321.61.
- Volume was 271.50K shares, 0.9x its 50-day average of 286.48K.
- Price is -3.9% vs its 50-day average ($340.41) and +7.9% vs its 200-day average ($303.20).
- 52-week range $179.19–$382.54; today's close sits at 73% of that range, 14.4% below the 52-week high.
Oct 7, 2026 — KRYS dips 0.7% to $324.57
- Closed at $324.57, -0.69% vs the prior close of $326.81. Day range $320.20–$330.44, opened at $324.87.
- Volume was 354.10K shares, 1.2x its 50-day average of 287.80K.
- Price is -4.9% vs its 50-day average ($341.13) and +7.2% vs its 200-day average ($302.77).
- 52-week range $179.19–$382.54; today's close sits at 71% of that range, 15.2% below the 52-week high.
Oct 6, 2026 — KRYS dips 2.4% to $326.81
- Closed at $326.81, -2.40% vs the prior close of $334.85. Day range $319.61–$335.16, opened at $335.16.
- Volume was 352.00K shares, 1.2x its 50-day average of 291.51K.
- Price is -4.4% vs its 50-day average ($341.92) and +8.1% vs its 200-day average ($302.31).
- 52-week range $179.19–$382.54; today's close sits at 73% of that range, 14.6% below the 52-week high.
Oct 5, 2026 — KRYS jumps 3.9% to $334.85
- Closed at $334.85, +3.90% vs the prior close of $322.28. Day range $321.36–$339.69, opened at $323.76.
- Volume was 337.00K shares, 1.1x its 50-day average of 295.17K.
- Price is -2.2% vs its 50-day average ($342.42) and +10.9% vs its 200-day average ($301.86).
- 52-week range $179.16–$382.54; today's close sits at 77% of that range, 12.5% below the 52-week high.
Oct 2, 2026 — KRYS dips 0.9% to $322.28, a 1-month low, 5 down days in a row
- Closed at $322.28, -0.93% vs the prior close of $325.31. Day range $320.29–$329.22, opened at $326.75.
- Volume was 425.60K shares, 1.1x its 50-day average of 380.05K.
- Price is -5.9% vs its 50-day average ($342.43) and +6.9% vs its 200-day average ($301.37).
- 52-week range $178.61–$382.54; today's close sits at 70% of that range, 15.8% below the 52-week high.
- That makes 5 straight losses.
KRYS latest news & SEC filings
Every SEC filing by or about KRYS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $119.22M (prior year $96.04M) (+24.1% vs Jun 30, 2025)
- Net income: $54.77M (prior year $38.33M) (+42.9% vs Jun 30, 2025)
- Diluted EPS: $1.79 (prior year $1.29) (+38.8% vs Jun 30, 2025)
Jul 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade KRYS
- Last results release: Aug 3, 2026 (8-K Item 2.02). Previous ones: Feb 17, 2026, Jan 12, 2026, Nov 3, 2025. Based on that rhythm, the next report is likely around Nov 2, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.83% (largest 5.1%).
- Liquidity: about 266.00K shares (≈$84.21M) trade per day on average.
- 52-week position: $316.58 vs a range of $183.03–$382.54 (67% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Krish S Krishnan sold 1,358 shares on Sep 4, 2026.
- Latest filings: 8-K Oct 15, 2026; 8-K Aug 3, 2026; 10-Q Aug 3, 2026.
- Share count: 29.60M shares outstanding (Jul 28, 2026), +2.3% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
KRYS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 329.94 | 331.02 | 315.39 | 316.58 | 226.22K |
| Oct 15, 2026 | 332.98 | 338.91 | 328.51 | 330.00 | 288.00K |
| Oct 14, 2026 | 320.41 | 330.96 | 319.01 | 330.69 | 277.40K |
| Oct 13, 2026 | 331.48 | 331.93 | 320.95 | 321.16 | 281.30K |
| Oct 12, 2026 | 329.14 | 334.27 | 328.53 | 332.07 | 168.10K |
| Oct 9, 2026 | 326.55 | 333.56 | 323.87 | 331.61 | 196.90K |
| Oct 8, 2026 | 321.61 | 332.11 | 319.58 | 327.30 | 271.50K |
| Oct 7, 2026 | 324.87 | 330.44 | 320.20 | 324.57 | 354.10K |
| Oct 6, 2026 | 335.16 | 335.16 | 319.61 | 326.81 | 352.00K |
| Oct 5, 2026 | 323.76 | 339.69 | 321.36 | 334.85 | 337.00K |
| Oct 2, 2026 | 326.75 | 329.22 | 320.29 | 322.28 | 425.60K |
| Oct 1, 2026 | 332.51 | 334.52 | 325.22 | 325.31 | 225.70K |
| Sep 30, 2026 | 336.56 | 337.03 | 331.80 | 332.56 | 268.30K |
| Sep 29, 2026 | 334.62 | 338.48 | 331.78 | 335.06 | 225.80K |
| Sep 28, 2026 | 347.00 | 350.00 | 334.01 | 337.08 | 298.90K |
| Sep 25, 2026 | 346.34 | 347.74 | 341.90 | 345.82 | 200.00K |
| Sep 24, 2026 | 341.85 | 345.48 | 336.56 | 344.96 | 222.50K |
| Sep 23, 2026 | 353.84 | 353.84 | 337.58 | 341.75 | 215.90K |
| Sep 22, 2026 | 334.76 | 353.83 | 334.31 | 350.88 | 274.50K |
| Sep 21, 2026 | 339.48 | 341.15 | 332.43 | 333.85 | 210.30K |
About Krystal Biotech
Krystal Biotech (KRYS) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in PITTSBURGH, PA. Fiscal year ends December 31. SEC CIK 1711279.
KRYS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Julian S Gangolli | Director | Sep 16, 2026 |
| Daniel Janney | Director | Sep 16, 2026 |
| Krish S Krishnan | President and CEO | Sep 4, 2026 |
| Suma Krishnan | President, R&D | Sep 4, 2026 |
| Christopher Mason | Director | Sep 16, 2026 |
| Catherine Mazzacco | Director | Sep 16, 2026 |
| Dino A Rossi | Director | Sep 16, 2026 |
| Everett Rand Sutherland | Director | Sep 16, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Laurent Louis Jean Goux | EVP, Head of International | Mar 6, 2026 |
| Krish S Krishnan | President and CEO | Sep 4, 2026 |
| Suma Krishnan | President, R&D | Sep 4, 2026 |
| Kathryn Romano | Chief Accounting Officer | Mar 3, 2026 |
| John Charles Thomas | EVP, General Counsel | Jun 26, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 4, 2026 | Krish S Krishnan | Sale | 1,358 | $364.48 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 847 | $365.42 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 405 | $366.56 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 520 | $354.54 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 2,029 | $355.57 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 3,297 | $356.37 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 3,981 | $357.57 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 3,143 | $358.42 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 3,357 | $359.39 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 2,266 | $360.46 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 1,214 | $361.61 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 2,010 | $362.65 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 573 | $363.34 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 1,358 | $364.48 |
| Sep 4, 2026 | Krish S Krishnan | Sale | 847 | $365.42 |
KRYS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $389.13M | $204.83M | 6.84 | $200.87M |
| Dec 31, 2024 | $290.51M | $89.16M | 3.00 | $123.42M |
| Dec 31, 2023 | $50.70M | $10.93M | 0.39 | $-88.80M |
| Dec 31, 2022 | $0 | $-139.97M | -5.49 | $-100.57M |
| Dec 31, 2021 | $0 | $-69.57M | -3.13 | $-47.94M |
Latest balance sheet: total assets $1.50B, total liabilities $141.52M, cash $427.74M (as of Jun 30, 2026).
KRYS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 3, 2026 | 8-K Item 2.02 (results) | $312.57 |
| Feb 17, 2026 | 8-K Item 2.02 (results) | $287.84 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $272.13 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $197.85 |
| Aug 4, 2025 | 8-K Item 2.02 (results) | $134.94 |
| May 6, 2025 | 8-K Item 2.02 (results) | $139.47 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $170.85 |
| Aug 5, 2024 | 8-K Item 2.02 (results) | — |
| May 6, 2024 | 8-K Item 2.02 (results) | — |
| Feb 26, 2024 | 8-K Item 2.02 (results) | — |
| Nov 6, 2023 | 8-K Item 2.02 (results) | — |
| Aug 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on KRYS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.